Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D01JPL
|
||||
Former ID |
DNCL003819
|
||||
Drug Name |
VEGFR3 Monoclonal Antibody
|
||||
Indication | Cancer [ICD9: 140-229; ICD10:C00-C96] | Phase 1 | [1] | ||
Company |
Lilly
|
||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 3 | Target Info | Modulator | [2] | |
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
PI3K-Akt signaling pathway | |||||
Focal adhesion | |||||
NetPath Pathway | TNFalpha Signaling Pathway | ||||
Pathway Interaction Database | VEGF and VEGFR signaling network | ||||
VEGFR3 signaling in lymphatic endothelium | |||||
Reactome | VEGF binds to VEGFR leading to receptor dimerization | ||||
WikiPathways | Signaling by VEGF | ||||
References | |||||
REF 1 | J Clin Oncol 29: 2011 (suppl, abstr TPS150). | ||||
REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1814). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.